Estilsona

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estilsona

What is Estilsona? (Prednisolone Steaglate)

Property Description
Active Ingredient Prednisolone Steaglate
Form Oral Drops in Suspension
Pharmacological Class Corticosteroid (Glucocorticoid)
Common Use Suppression of inflammation and immune activity
Origin Synthetic
RX Status Prescription-only (R)

1. What Type of Medicine is Estilsona?

Estilsona is an established medicinal product based on Prednisolone Steaglate, an active chemical substance classified pharmacologically as a potent, synthetic glucocorticoid within the broader corticosteroid class. The drug is synthesized to act as a powerful agent against immune overactivity by mimicking and amplifying the actions of the natural hormone, cortisol. This compound is distinguished from generic formulations by its preparation as oral drops in suspension, a format that facilitates precise dosing, making it particularly suitable for pediatric and systemic use.

2. Composition and Available Preparations

The therapeutic effect of Estilsona is centered on its sole active substance, Prednisolone Steaglate, ensuring effective absorption via the oral route. This specific formulation is delivered as a suspension intended to be taken by calibrated drops or oral syringe. The overall anti-inflammatory function of prednisolone provides a powerful and reliable action. The drug’s utility is further enhanced by its preparation in an aqueous vehicle, which is necessary for stable and effective delivery.

3. What is the General Purpose of This Glucocorticoid?

The overarching purpose of this potent glucocorticoid is the robust suppression of both excessive inflammation and an overactive immune system. It operates by interrupting the underlying sequence of cellular events that generate persistent inflammatory signs, such as swelling and pain, providing a rapid-acting therapeutic effect. A typical use scenario involves its application in managing acute exacerbations of allergic and inflammatory disorders where rapid, systemic control of the response is medically necessary. The fundamental benefit is the systemic relief provided by its powerful immunosuppressive action.

Regulatory References

  1. WHO Model List of Essential Medicines (Prednisone)
  2. Prednisolone: MedlinePlus Drug Information

What side effects are possible with Estilsona?

Possible Side Effects and Safety Information

The safety profile for this medicine is officially documented based on the known risks of its active ingredients, a systemic corticosteroid (e.g., Prednisone/Prednisolone) and an antihistamine (Chlorphenamine/Chlorpheniramine).

System Organ Class Adverse Reactions

Adverse effects are categorized by the body systems they affect, reflecting the widespread influence of corticosteroids. Major categories include Endocrine and Metabolic Disorders, which involve HPA axis suppression and fluid retention; Musculoskeletal Disorders such as osteoporosis; and Psychiatric Disorders, including mood changes and severe depression. The antihistamine component contributes to Nervous System Disorders like drowsiness and dizziness, and Gastrointestinal effects like dry mouth.

Serious Adverse Reactions

Regulatory sources define specific serious and clinically significant risks. These include the potential for Peptic Ulceration (which may lead to bleeding or perforation), severe hypersensitivity reactions, Glaucoma or Cataracts, and the risk of Acute Adrenal Insufficiency if the corticosteroid is withdrawn too quickly after prolonged use. Myocardial rupture following a recent heart attack is also a serious, documented risk.

Safety-Related Restrictions

Use is contraindicated in patients with documented hypersensitivity to the components and in those with systemic fungal infections. Caution and close monitoring are officially mandated in patients with known pre-existing conditions such as diabetes mellitus, a history of peptic ulcer disease, glaucoma, uncontrolled hypertension, or certain severe affective disorders, as these risks may be exacerbated. The elderly population requires particular caution due to increased vulnerability to certain side effects.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Estilsona (Prednisolone Steaglate) is defined by the potential for acute, severe manifestations resulting from massive overexposure, which may parallel the toxicity seen with other high-dose corticosteroids.

Documented Overdose Manifestations (Signs and Symptoms)
Neuropsychiatric Effects: Seizures (convulsions), severe confusion, psychosis, or frank loss of contact with reality [DailyMed].
Systemic Signs: Hypertension (high blood pressure), irregular heartbeat, and metabolic changes such as hyperglycemia (high blood sugar) [MedlinePlus].
Gastrointestinal Risk: Severe complications including peptic ulcer perforation or hemorrhage [DailyMed].

Emergency Actions Required
Immediate Medical Help is Required: Contact emergency services immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened (unconsciousness) [MedlinePlus].
General Guidance: For non-severe cases, contact with the Poison Control Helpline is advised for specific instructions [MedlinePlus].

Management and Antidote Information
Antidote: No specific antidote is known for this overdose.
Management: Treatment is symptomatic and supportive, focusing on clinical manifestations and requiring hospital monitoring of vital signs, blood pressure, and serum electrolyte levels [DailyMed].

These official statements define the required urgent response, emphasizing that the absence of a specific reversal agent necessitates immediate medical intervention and specialized monitoring to manage the resulting systemic and severe neurological toxicity.

Therapeutic Uses of Estilsona

What Estilsona Treats: Main Uses and Benefits

Estilsona (Prednisolone Steaglate) is commonly used to provide symptomatic relief across multiple clinical domains that involve significant inflammatory or immune-mediated distress. As a corticosteroid, it is applied to address a broad range of conditions that cause symptoms related to systemic imbalance and affects organ-specific functional stress, along with systemic symptoms. The oral drops formulation is particularly relevant for the pediatric group and for patients who may have difficulty with tablet forms.

This medication is used for managing symptom clusters that may become intense or disruptive, offering supportive relief in conditions characterized by periods of heightened symptoms, such as rheumatic diseases, inflammatory bowel disease (IBD) flares, and severe asthma exacerbations. It is applied across domains where additional symptomatic support is needed.

“This medicine may be relevant for easing symptoms related to inflammatory or irritative states and supporting patients during difficult episodes.”


Quick Fact: Relief for Widespread Symptom Clusters
Common Use Context Applied in clinical settings that involve acute or unstable symptom patterns, such as severe flares of autoimmune or allergic conditions.
Primary Benefit Provides supportive relief that helps ease the symptom load and contributes to improved comfort during periods of heightened symptoms.
Patient Group Relevance Commonly used for children and patients requiring liquid administration for systemic effect.

Applied in scenarios where additional management of discomfort is required, the medication may assist with maintaining functional stability, providing supportive relief when symptoms interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official eligibility profile for Estilsona (prednisolone) strictly defines the populations who may or may not use the medicine, based on regulatory documentation from bodies like the FDA and EMA.

Contraindications and Restrictions

Estilsona is absolutely contraindicated for patients with a documented hypersensitivity to prednisolone or other ingredients, as well as those with active systemic fungal infections. Live or live attenuated vaccines should not be given to individuals receiving immunosuppressive doses of the medicine.

Use requires great caution and monitoring in patients with specific, uncontrolled comorbidities. These include a history of or current peptic ulcers, diabetes mellitus (due to the risk of increased blood sugar), uncontrolled hypertension, or severe congestive heart failure.

Special Populations

Population Group Official Regulatory Status
Pediatric Patients Safety and efficacy are not established in infants under certain age thresholds for specific indications. Long-term use requires monitoring for potential growth suppression.
Pregnancy Use is generally restricted to when the benefit outweighs the risk to the fetus. Infants exposed to substantial doses should be monitored for adrenal suppression.
Lactation Caution is advised. Prednisolone passes into breast milk in small amounts; monitoring of the infant for adrenal suppression may be required if maternal doses exceed 40 mg/day.

These constraints establish the formal regulatory boundary for who can and cannot safely use this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estilsona (Prednisolone Steaglate) has officially documented interaction patterns primarily through metabolic and pharmacodynamic mechanisms, as specified in regulatory labeling.

Pharmacokinetic and Exposure-Altering Interactions

Co-administration with medicines that induce the CYP 3A4 enzyme system (e.g., rifampin, phenytoin) may increase the clearance of the corticosteroid, potentially leading to decreased plasma concentration and effect. Conversely, strong CYP 3A4 inhibitors (e.g., ketoconazole, erythromycin) may decrease the clearance of the corticosteroid, which can result in increased systemic exposure and concentration. Additionally, Estrogens (including oral contraceptives) may also increase the corticosteroid's effect by decreasing its hepatic metabolism. Aminoglutethimide is documented to potentially lead to a loss of corticosteroid-induced adrenal suppression.

Pharmacodynamic and Restriction-Based Interactions

The co-administration of live or live attenuated vaccines is contraindicated when the patient is receiving immunosuppressive doses of the corticosteroid. Antidiabetic agents may have their effects antagonized, as the corticosteroid may increase blood glucose concentrations. Concurrent use with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including salicylates, is associated with an increased risk of gastrointestinal side effects. The medication may also alter the effect of oral anticoagulants, necessitating the monitoring of coagulation indices. Furthermore, Anticholinesterase agents must be withdrawn at least 24 hours prior to initiating corticosteroid therapy, if medically possible, due to the risk of severe weakness.

Mechanism of Action

How Estilsona Works

The mechanism of action for Estilsona is attributed to the activity of Prednisolone, a synthetic glucocorticoid that engages complex genomic mechanisms, altering inflammatory and immune pathways. Its function is categorized by three core mechanistic domains.


1. Molecular Targeting and Gene Expression Control

This mechanism involves Prednisolone acting as an agonist for the ubiquitous Glucocorticoid Receptor ( GR), which then translocates to the cell nucleus to alter gene transcription. This process alters cellular behavior by increasing the synthesis of inhibitory proteins while reducing the transcription of pro-inflammatory genetic instructions.


2. Transcriptional Blockade of Inflammatory Pathways

The activated GR complex exerts its action primarily through transrepression, functionally shutting down major pro-inflammatory transcription factors like NF-kappa B and AP-1. This interference modifies early molecular steps in the inflammatory cascade, resulting in a reduction in the synthesis of mediators such as cytokines, prostaglandins, and leukotrienes.


3. Immune Cell Modulation and Systemic Effect

The mechanism results in a downstream physiological effect that includes suppressing the function and inducing the programmed cell death of certain immune cells, while also reducing the expression of molecules required for immune cells to migrate into affected tissues. This adjustment to activity within peripheral pathways affects the movement and function of the immune response cells.

Dosage and Administration Information

Estilsona (Prednisolone Steaglate) is an oral-route medication provided as a liquid suspension, meaning it is taken by mouth. Every dose must be measured using a special, calibrated measuring device, such as an oral syringe or dropper, to ensure accuracy, as household measures are insufficient.

Official Dosing and Frequency

Dosage is highly individualized based on the required systemic effect of the active ingredient. Initial adult dose ranges typically fall between 5 mg and 60 mg per day of prednisolone, with the goal being the lowest dosage that maintains the required response. The medication may be scheduled for administration once daily, often in the morning to align with the body's natural corticosteroid production, or in divided doses throughout the day.

Administration Context and Duration

To help reduce the potential for gastrointestinal irritation, the medicine should be taken with food or milk. Dosing for the pediatric population is calculated based on body weight or surface area. Patients with hepatic or renal impairment may require an adjustment to their prescribed regimen due to changes in drug clearance.

For any use that is prolonged or involves high doses, the treatment must not be stopped suddenly. The medication involves a gradual reduction (tapering) in dose upon discontinuation to prevent complications, defining a structured process for ending the course of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Estilsona (Prednisolone Steaglate)


Evidence for Use in Acute Asthma Exacerbations

Estilsona's active component, Prednisolone, was evaluated in research exploring conditions characterized by heightened symptom activity, such as acute asthma attacks or episodes of severe wheezing. Researchers primarily used Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews to investigate the effects of short-term, systemic glucocorticoid administration. These studies mainly included both children and adults presenting with unstable or episodic symptom patterns in emergency or hospital settings.

The research examined outcomes related to physical discomfort and acute changes. Studies frequently monitored changes in objective measures like pulmonary function tests (for example, FEV1 or peak flow) and clinical outcomes such as the need for hospital admission. Findings describe patterns observed in the studies where short-term physiological changes were measured during the immediate study period. However, the evidence largely applies to the general class of oral corticosteroids, and long-term effects are not fully established, particularly concerning the use of repeated short courses in children.


Evidence for Use in Croup (Laryngotracheitis)

Systemic corticosteroids were evaluated in studies researching how symptoms change over time in children with conditions characterized by fluctuating manifestations, like croup. The research base was studied extensively, relying heavily on Meta-analyses of multiple Randomized Controlled Trials. These studies focused on hospitalized children and aimed to evaluate outcomes linked to inflammatory or irritative states affecting the airway.

Research examined outcomes capturing phases of heightened symptom activity, using standardized measures like the Westley Croup Score to objectively track changes in symptom intensity. Trials monitored outcomes related to systemic or functional imbalance, such as the duration of hospital stay. A key research limitation is that many high-quality studies on croup focus on other glucocorticoids, such as dexamethasone, meaning evidence specifically about Prednisolone Steaglate is often an extrapolation based on the recognized effects of the class.


What is Still Uncertain About Estilsona Research

Comparative evidence is lacking for many direct, head-to-head comparisons of the specific Prednisolone Steaglate formulation against all available alternatives. The systemic use of glucocorticoids was observed in research exploring acute inflammatory and immune-mediated conditions, but the follow-up durations were limited in many acute-care trials, meaning long-term outcomes are not fully established. Furthermore, the findings for certain subgroups often rely on older studies where sample sizes were modest, leaving certain aspects of the evidence uncertain.

Frequently Asked Questions (FAQ)

Common questions about Estilsona (FAQ)


Q: How long does it typically take to see the effects of Estilsona?

A: Studies focusing on the drug class indicate that the active component, prednisolone, is released and metabolized rapidly by the body. According to official data, substantial levels of the medicine are generally attained in the bloodstream within about 30 minutes of administration. The time required for an individual to observe therapeutic effects may vary depending on the condition being addressed.


Q: Are there any common foods or drinks that interact with Estilsona?

A: Official patient guidance describes that reducing salt (sodium) intake is commonly advised while using this medicine, due to the potential for fluid retention. Label-aligned information notes that caution is often recommended regarding large amounts of caffeine, found in drinks like coffee or soda, because of the risk of increased sleep disturbance.


Q: Is it true that Estilsona can cause insomnia?

A: Yes, official product information lists trouble sleeping and insomnia as documented side effects. This can happen because the medicine mimics natural hormones that play a role in regulating the body's sleep-wake cycle.


Q: What makes Estilsona different from other corticosteroids?

A: The medicine is distinct from other corticosteroids primarily in its form and its active ingredient. It is formulated as an Oral Drops in Suspension, which helps allow for precise measurement. Its active component is Prednisolone Steaglate, which is a specific salt form of prednisolone designed for oral delivery.


Q: What is the longest time a person can safely use Estilsona?

A: There is no single, standard maximum time limit for treatment, as use is highly individualized. Regulatory-aligned literature generally differentiates between short-term use (e.g., less than one month) and long-term use (e.g., more than three months). Longer courses of treatment are described in regulatory documents as being associated with an increased potential for certain side effects.


Q: Are there published studies about the long-term use of Estilsona?

A: Yes, systematic reviews and studies have examined the effects of prolonged systemic corticosteroid use. This research documents associations with adverse events such as changes in bone density (like fracture risk) and increased risk of infection.


Q: What if I forget to take Estilsona, what's the general guidance?

A: For a once-daily regimen, the general guidance is to take the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the regulatory-aligned guidance suggests skipping the missed dose and proceeding with the subsequent dose at the usual time. It is stated that taking two doses simultaneously to compensate for a missed dose should be avoided.


Q: Does Estilsona have a risk of dependency or addiction?

A: The medicine is not typically considered addictive in the traditional sense of substance abuse. However, regulatory information states that physical dependency can develop with prolonged use because it suppresses the adrenal glands' natural production of the hormone cortisol. This physical effect necessitates a gradual reduction (tapering) in dose when the medicine is discontinued.


Q: Is Estilsona considered a short-term or long-term medication?

A: Treatment duration is determined by the specific medical need, but regulatory-aligned clinical literature generally classifies courses lasting less than one month as short-term. Treatment continuing for more than three months is typically considered long-term use, due to the associated safety and risk profiles.


Q: What is the difference between Estilsona and the generic version of the drug?

A: Estilsona is the brand name for the Prednisolone Steaglate active ingredient, delivered as a specific oral suspension formulation. A generic version would contain a form of Prednisolone, but the specific salt form and the medicine's physical preparation (the liquid formulation) may differ from the brand name product.


Q: How does Estilsona affect children compared to adults?

A: Regulatory information emphasizes the need for close monitoring in children due to specific risks associated with systemic corticosteroids. The regulatory label specifically notes that potential growth suppression and changes in blood pressure and blood sugar levels are important parameters for monitoring during long-term use.


Q: Is it common to gain weight while taking Estilsona?

A: Increased appetite and weight gain are commonly reported side effects of this class of medicine. Official safety information notes that this may also be related to the medicine causing fluid retention in the body.


Q: What does the research say about Estilsona's use in autoimmune disorders?

A: According to official documents, the active component, Prednisolone, is used to treat a wide range of inflammatory conditions and autoimmune disorders. It is listed on the World Health Organization (WHO) List of Essential Medicines for its role as a systemic glucocorticoid.


Q: Can Estilsona be taken with common cold and flu medicines?

A: Official patient information emphasizes that consultation with a healthcare professional regarding all over-the-counter and common cold or flu medicines is an important precaution before use. This is because many different drugs can potentially alter the effect of the corticosteroid or increase the risk of side effects.


Q: What is the half-life of Estilsona, if publicly available?

A: The active component of the medicine is Prednisolone, which has a biological half-life that typically ranges from 12 to 36 hours. The half-life is a measure of the time it takes for the concentration of the medicine's active substance to be reduced by half in the body.


Q: Does Estilsona require any special monitoring while being used?

A: Yes, regulatory labeling advises or mandates specific monitoring while using this medication. This monitoring includes checks for changes in vision, and routine monitoring of blood pressure and blood sugar levels. Tracking the growth rate is also advised for pediatric patients.


Q: Are there certain groups of people for whom Estilsona is generally less effective?

A: Research into the corticosteroid drug class has identified patient groups, particularly those with severe asthma or other chronic inflammatory diseases, who may exhibit a reduced responsiveness to the medicine. This is sometimes referred to as a form of corticosteroid resistance.


Q: Is it normal to feel more energetic or restless after taking Estilsona?

A: Yes, psychological effects are documented in official safety information. Users may experience changes in mood and behavior, which can include feeling more energetic, experiencing restlessness, or having other emotional changes.


Q: Are there any known interactions with herbal supplements and Estilsona?

A: According to regulatory-aligned patient information, there is limited information available on specific interactions with most herbal supplements or teas. Due to the potential for unforeseen effects or interaction with the immune-suppressing action, official guidance suggests that consultation with a healthcare professional is necessary before using any herbal products.


Q: What are the signs of stopping Estilsona too quickly?

A: Stopping the medicine suddenly after prolonged use can lead to a serious complication called Acute Adrenal Insufficiency. Signs of this serious issue may include extreme fatigue and weakness, dizziness, severe nausea/vomiting, and significantly low blood pressure.


Q: Is Estilsona used to treat skin conditions like eczema or psoriasis?

A: The active component, Prednisolone, is officially indicated as a systemic treatment to manage a variety of inflammatory skin diseases. This includes conditions such as eczema (dermatitis).


Q: Does Estilsona carry a black box warning from the FDA, or similar warnings from other agencies?

A: While the term 'Black Box Warning' (a specific US designation) may not be universally applied, the medication does carry mandatory serious warnings from regulatory agencies. These prominent warnings highlight critical risks such as adrenal suppression and the potential for the drug to mask the signs of an infection.


Q: Can Estilsona cause trouble sleeping?

A: Yes, official product information lists trouble sleeping and insomnia as documented side effects. This can happen because the medicine mimics natural hormones that play a role in regulating the body's sleep-wake cycle.

How should Estilsona be stored and disposed of?

How to Store and Dispose of Estilsona?

  • Storage: Estilsona oral suspension drops should typically be stored at room temperature (between 59°F and 77°F or 15^circC and 25^circC) in a cool, dry place. It does not generally require special storage conditions, such as refrigeration. Always check the original package or patient leaflet for specific instructions and ensure the bottle is closed well after each use. Keep all medicines, including Estilsona, securely out of the sight and reach of children and pets. Do not use the medicine past the expiration date printed on the packaging.

  • Disposal: The preferred method for disposing of unused or expired Estilsona, like most medicines, is through a community drug take-back program or an authorized disposal location. Many pharmacies offer on-site disposal kiosks. If a take-back option is unavailable, the suspension may be mixed with an undesirable substance (e.g., dirt, cat litter, or used coffee grounds), placed in a sealed container, and then discarded in the household trash. Do not flush this medicine down the toilet or pour it down a sink unless specifically instructed to do so by the manufacturer or the FDA 'flush list.' Remove all personal information from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estilsona found in:

A-Z Index: